The survival analysis indicated that glioma patients with lower expression of CAMK1D in TCGA (HR: 0.33, 95% CI 0.25–0.44), CGGA (HR: 0.60, 95% CI 0.51–0.71), Rembrandt (HR: 0.54, 95% CI 0.43–0.68), Gravendeel (HR: 0.56, 95% CI 0.43–0.73), Kamoun (HR: 0.81, 95% CI 0.44–1.49), Phillips (HR: 0.43, 95% CI 0.26–0.73), Freije (HR: 1.04, 95% CI 0.62–1.73), and LeeY (HR: 0.85, 95% CI 0.63–1.14) exhibited significantly shorter survival time than patients with higher expression, while patients from the Kamoun cohort displayed the same trend with no statistical significance (Figure 2A). Here, CAMK1D is linked to glioma.